February 21st 2019
The 4-drug combination of rituximab, bendamustine, bortezomib, and dexamethasone was found to improve progression-free survival and demonstrated a tolerable safety profile as frontline treatment for patients with mantle cell lymphoma who are ≥65 years.
January 22nd 2019
Maria-Victoria Mateos, MD, PhD, discusses the updated findings from the ALCYONE trial in patients with newly diagnosed multiple myeloma.
January 15th 2019
Krish Patel, MD, discusses some of the most significant mantle cell lymphoma data presented during the 2018 ASH Annual Meeting and how the use of BTK inhibitors will evolve going forward.
August 10th 2018
The PD-L1 immunohistochemistry 22C3 pharmDx can be an aid in identifying patients with non–small cell lung cancer and gastrointestinal cancers who are eligible for pembrolizumab (Keytruda) monotherapy.
May 3rd 2018
Immunotherapy has arrived in the gastrointestinal cancer landscape, and while not all patients will benefit from these agents, those who do are likely to have long-lasting responses, explained John L. Marshall, MD.
March 13th 2018
Jarushka Naidoo, MBBCh, discusses some of the most commonly seen immune-related adverse events in patients with lung cancer and how to manage them.
March 11th 2018
Heather Wakelee, MD, discusses the rapidly changing landscape of frontline EGFR tyrosine kinase inhibitors in non–small cell lung cancer.
February 16th 2018
Hope S. Rugo, MD, discusses the importance of individualizing doses of nab-paclitaxel in triple-negative breast cancer.
October 27th 2017
Paul A. Bunn Jr, MD, discusses strategies for analyzing and responding to signs of progression for patients receiving immunotherapy for non-small cell lung cancer.
August 13th 2017
Lisa Carey, MD, discusses the challenges with de-escalation in patients with TNBC and steps toward overcoming these obstacles.
August 10th 2017
Arti Hurria, MD, discusses the unique challenges with treating elderly patients with breast cancer and the exciting opportunities she envisions for advancing care in this setting.
August 9th 2017
Mark Pegram, MD, discusses emerging treatments in HER2-positive breast cancer and his vision for the future of the field.
June 30th 2017
Jeffrey S. Weber, MD, PhD, discusses the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the treatment of brain metastases, the tolerability of the combination of ipilimumab and talimogene laherparepvec (Imlygic; T-VEC), and what is next on the horizon for pembrolizumab (Keytruda).
June 20th 2017
Christophe Massard, MD, PhD, discusses the latest developments with durvalumab (Imfinzi) in urothelial carcinoma.
May 5th 2017
Richard M. Stone, MD, discusses the impact that midostaurin could have for patients with AML, as well as ongoing research with the agent.
April 28th 2017
Leah Ralph discusses the ACCC’s position on the Afforadable Care Act repeal bill, the Medicare Payment Advisory Commission’s Part B cost control proposals, and the possibility for comprehensive reform on the 340B Drug Discount Program.
April 26th 2017
Dana Chase, MD, discusses obstacles to progress and her hope for the future in advanced gynecologic cancers.
April 24th 2017
Leonard Gomella, MD, discusses the future of biomarkers in prostate cancer.
April 20th 2017
Matthew B. Yurgelun, MD, discusses a study that determined that nearly 10% of patients with colorectal cancer had germline cancer susceptibility gene mutations and its implications for patients and their families.